Actelion analyst call presages fireworks at AGM?
This article was originally published in Scrip
Executive Summary
Board members at Actelion, the Swiss speciality pharma company, got an early taste on 17 February of the reception they might get when they address shareholders at the company's AGM on 5 May. Dominic Dolinetz from Elliott Advisors, a hedge fund that has a 6% stake in the company, took the microphone during the presentation of Actelion's 2010 results to berate the company's management for stifling discussion and undermining shareholder value. The accusations were robustly rebutted by Dr Jean-Paul Clozel, Actelion's CEO.